Steven Chappell Mitchell

Title: Innovations of Steven Chappell Mitchell

Introduction

Steven Chappell Mitchell is an accomplished inventor based in Gurnee, IL (US). He holds a total of 11 patents that contribute significantly to the field of cancer research. His work primarily focuses on the development of novel antigens that have potential applications in cancer diagnostics and therapeutics.

Latest Patents

One of his latest patents is titled "Serpentine transmembrane antigens expressed in human cancers and uses thereof." This patent describes a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer. These members have been termed 'STEAP' (Six Transmembrane Epithelial Antigen of the Prostate). The patent details four particular human STEAPs, which exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, is characterized as a type IIIa membrane protein predominantly expressed in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini. This suggests that it folds in a 'serpentine' manner into three extracellular and two intracellular loops. Another member, STEAP-2, is a 454 amino acid protein with a similar predicted molecular topology.

Career Highlights

Throughout his career, Steven has worked with notable companies such as Agensys, Inc. and Genentech, Inc. His contributions to these organizations have been instrumental in advancing cancer research and developing innovative therapeutic solutions.

Collaborations

Steven has collaborated with esteemed colleagues, including Rene S Hubert and Arthur B Raitano. These partnerships have further enriched his research and development efforts in the field of cancer diagnostics.

Conclusion

Steven Chappell Mitchell's innovative work in the development of serpentine transmembrane antigens has the potential to significantly impact cancer treatment and diagnostics. His contributions to the field are noteworthy and continue to inspire advancements in medical research.